Given the alarming levels of spread and severity, quite a few biotechs are developing antibodies or evaluating their approved drugs or pipeline candidates to determine if they are effective in treating the infected patients.Earlier, Incyte INCY initiated RUXCOVID, a global, randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of Jakafi plus SoC in patients 12 years and above with COVID-19-associated cytokine storm.